Skip to content

US · AZTA · MEDICAL - INSTRUMENTS & SUPPLIES

Azenta, Inc. (AZTA) intrinsic value and stock valuation

$44.80as of 2026-11-21 · Mkt cap 1.48B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Azenta, Inc. DCF and intrinsic value

InvestorsCraft values AZTA with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from AZTA’s statements →

Azenta, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Burlington, MA 01803 azenta.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$593.8M+8.9% 5y CAGRd
20112025
Net income
-$-55.76M
20112025
Free cash flow
$38.3M
20112025
Total equity
$1.73B+7.3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$593.8M$573.5M$665.1M$555.5M$513.7M
Operating income-$-11.27M-$-29.98M-$-82.2M-$-24.02M$3.6M
Net income-$-55.76M-$-164.9M-$-14.26M-$-428.96M$110.8M
EPSd-$-1.21M-$-3.1M-$-215.25K-$-5.73M$1.49M
Operating cash flow$72.2M$49.7M$5.83M-$-466.05M$149.9M
Capital expenditure-$-33.86M-$-37.39M-$-39.44M-$-77.44M-$-52.8M
Free cash flow$38.3M$12.4M-$-33.6M-$-543.48M$97.1M
Total assets$2.06B$2.1B$2.89B$3.72B$1.82B
Total debt$111.2M$70.7M$60.4M$49.2M$94.8M
Net debt-$-168.61M-$-240.25M-$-618.47M-$-609.05M-$-132.66M
Total equity$1.73B$1.77B$2.53B$3.36B$1.33B
Cash and short-term investments$340.9M$462.1M$1.02B$1.57B$227.5M
Income statement
20252024202320222021
Revenue$593.8M$573.5M$665.1M$555.5M$513.7M
Cost of revenue$323.5M$318.8M$431.8M$324.9M$299.2M
Gross profit$270.3M$254.6M$233.3M$230.6M$214.5M
Research and development expenses$30.4M$31.5M$34M$27.5M$22.4M
Selling, general and administrative expenses$251.2M$253.1M$281.5M$227.1M$188.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$281.6M$284.6M$315.5M$254.6M$210.9M
Cost and expenses$605.1M$603.4M$747.3M$579.5M$510.1M
Interest income$18.8M$33.2M$43.7M$20.3M$630K
Interest expense$0.00$0.00$0.00$4.59M$2.04M
Depreciation and amortization$61.2M$90.7M$85.6M$53.7M$56.9M
Ebitda$54.1M$71.6M$55.2M$48.4M$9.94M
Operating income-$-11.27M-$-29.98M-$-82.2M-$-24.02M$3.6M
Total other income/expenses, net$4.12M$10.9M$51.8M$14.1M-$-52.56M
Income before tax-$-7.14M-$-19.12M-$-30.43M-$-9.94M-$-48.97M
Income tax expense-$-31.6M$5.24M-$-17.55M$1.35M-$-20.1M
Net income-$-55.76M-$-164.9M-$-14.26M-$-428.96M$110.8M
Weighted average shares outstanding$45.7M$53.2M$66.3M$74.9M$74.2M
Weighted average diluted shares outstanding$45.9M$53.2M$66.3M$74.9M$74.5M
Balance sheet
20252024202320222021
Cash and short-term investments$340.9M$462.1M$1.02B$1.57B$227.5M
Net receivables$189.2M$172.7M$156.5M$163.8M$119.9M
Inventory$75M$115.3M$128.2M$85.5M$60.4M
Total current assets$708.3M$832.8M$1.42B$2.46B$777.4M
Property, plant and equipment, net$208M$266.7M$205.7M$154.5M$130.7M
Goodwill and intangible assets$804.2M$939.4M$1.08B$692M$655.9M
Long-term investments$247.2M$49.5M$111.3M$352M$3.6M
Total non-current assets$1.35B$1.27B$1.47B$1.26B$1.04B
Total assets$2.06B$2.1B$2.89B$3.72B$1.82B
Accounts payable$37.7M$44.4M$35.8M$38.7M$42.4M
Short-term debt$7.78M$10.6M$0.00$0.00$0.00
Deferred revenue$32.6M$32M$34.6M$39.8M$25.7M
Total current liabilities$237.7M$204.8M$210.9M$230.6M$345.1M
Long-term debt$103.4M$60.1M$60.4M$49.2M$94.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$93M$126.2M$140.3M$122.2M$149.1M
Capital lease obligations$52.2M$70.7M$60.4M$49.2M$45.1M
Total liabilities$330.7M$331.1M$351.2M$352.7M$494.2M
Common stock$590K$590K$710K$890K$880K
Retained earnings$1.42B$1.48B$1.64B$1.66B-$-470.05M
Accumulated other comprehensive income (loss)-$-22.21M-$-13.46M-$-62.43M-$-83.92M$19.4M
Total equity$1.73B$1.77B$2.53B$3.36B$1.33B
Total investments$308.3M$200.6M$450.2M$1.26B$3.68M
Total debt$111.2M$70.7M$60.4M$49.2M$94.8M
Net debt-$-168.61M-$-240.25M-$-618.47M-$-609.05M-$-132.66M
Cash flow statement
20252024202320222021
Net income-$-55.76M-$-164.9M-$-14.64M$2.13B$110.8M
Depreciation and amortization$61.2M$90.7M$85.6M$53.7M$65.3M
Stock-based compensation$20.9M$14.5M$9.38M$10.7M$27.5M
Change in working capital-$-22.84M$3.04M-$-29.04M-$-72.73M-$-51.21M
Accounts receivable-$-24.56M-$-12.07M$34.5M-$-31.4M-$-69.64M
Inventory-$-2.67M$15.9M$8.25M-$-66.63M-$-50.44M
Accounts payable$1.04M$9.2M-$-14.71M-$-3.93M$31M
Net cash provided by operating activities$72.2M$49.7M$5.83M-$-466.05M$149.9M
Investments in property, plant and equipment-$-33.86M-$-37.39M-$-39.44M-$-73.44M-$-52.8M
Acquisitions, net$0.00$0.00-$-386.51M$2.81B-$-95.51M
Net cash used for investing activities-$-90.46M$224.7M$431.4M$1.47B-$-146.35M
Common stock issued$2.77M$3.28M$3.62M$5.25M$5.81M
Common stock repurchased$0.00-$-661.7M-$-838.51M$0.00$0.00
Dividends paid$0.00$0.00$0.00-$-7.49M-$-29.73M
Net cash used for financing activities-$-9.59M-$-659.21M-$-840.46M-$-62.76M-$-25.91M
Net change in cash-$-24.3M-$-363.06M-$-357.25M$756M-$-17.19M
Cash at end of period$296.7M$321M$684M$1.04B$285.3M
Operating cash flow$72.2M$49.7M$5.83M-$-466.05M$149.9M
Capital expenditure-$-33.86M-$-37.39M-$-39.44M-$-77.44M-$-52.8M
Free cash flow$38.3M$12.4M-$-33.6M-$-543.48M$97.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Azenta, Inc.

        Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.

        CEO
        John Marotta
        Employees
        3K
        Beta
        1.37

        Explore

        Frequently asked questions

        What is the intrinsic value of Azenta, Inc. (AZTA)?

        Azenta, Inc. (AZTA) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AZTA undervalued?

        AZTA trades at a price of $44.80 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.